Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, recently named Dr. Steven Levin, M.D., to its scientific advisory board. An article further discussing the appointment reads, “‘Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain-management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,’ Alan Collier, CEO of Endonovo Therapeutics, said in a news release (http://nnw.fm/PeF8s). ‘As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.’ . . . Levin’s membership in professional and scientific societies has included the American Society of Anesthesiology, the American Pain Society, the American Society of Regional Anesthesia, the Society in Anesthesia and the International Association for the Study of Pain. He is currently the co-chair of the Opioid Stewardship Clinical Community, as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System.”
To view the full article, visit http://nnw.fm/zdN1H
About Endonovo Therapeutics Inc.
Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable electroceuticals(TM) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable electroceuticals therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive electroceutical therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema, and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical stage electroceuticals therapeutic devices addresses chronic kidney disease, liver disease nonalcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The company’s noninvasive, wearable electroceuticals therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com